Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial

Research output: Contribution to journalArticle

  • External authors:
  • Usha Chakravarthy
  • Simon P. Harding
  • Chris A. Rogers
  • Susan M. Downes
  • Andrew J. Lotery
  • Sarah Wordsworth
  • Barnaby C. Reeves

Abstract

Purpose: To compare the efficacy and safety of ranibizumab and bevacizumab intravitreal injections to treat neovascular age-related macular degeneration (nAMD). Design: Multicenter, noninferiority factorial trial with equal allocation to groups. The noninferiority limit was 3.5 letters. This trial is registered (ISRCTN92166560). Participants: People >50 years of age with untreated nAMD in the study eye who read

Bibliographical metadata

Original languageEnglish
Pages (from-to)1399-1411
Number of pages12
JournalOphthalmology
Volume119
Issue number7
DOIs
Publication statusPublished - Jul 2012